System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Interventional Recruiting Phase 1/Phase 2

NCT06527495 on ClinicalTrials.gov

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

Official title: Clinical Pharmacogenetic Study of the Efficacy and Safety of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

  • Sponsor: Assiut University
  • Enrollment: 150 (Estimated)
  • Study start: 2023-01-01 (Actual)
  • Primary completion: 2024-12-01 (Estimated)
  • Study completion: 2024-12-01 (Estimated)
  • Allocation: N/a
  • InterventionModel: Single Group
  • Masking: None
  • PrimaryPurpose: Treatment

Brief Summary

The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.

Conditions

  • HCC
  • Hepatocellular Carcinoma

Intervention / Treatment

  • Drug: Sorafenib

Primary Outcome Measures

  • Vascular Endothelial Growth Factor A (VEGFA) genotyping (At Baseline, 3 month, and 6 month after treatment.)
    Genetic polymorphism of VEGFA
  • Kinase insert domain receptor (KDR) genotyping (At Baseline, 3 month, and 6 months after treatment.)
    Genetic polymorphism of KDR

Countries

Egypt

Locations and Investigators

  • NLI, ShibÄ«n Al Kawm, Egypt (Recruiting)